Health-related quality of life and disease-specific complaints among multiple myeloma patients up to 10 yr after diagnosis: results from a population-based study using the PROFILES registry.
about
Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis.Integrating patient reported outcomes with clinical cancer registry data: a feasibility study of the electronic Patient-Reported Outcomes From Cancer Survivors (ePOCS) system.Health-related quality of life in older adult survivors of selected cancers: data from the SEER-MHOS linkage.Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience.Incidence and risk factors for suicide and attempted suicide following a diagnosis of hematological malignancy.Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide.The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study.The influence of baseline characteristics and disease stage on health-related quality of life in multiple myeloma: findings from six randomized controlled trials.Quality of life and supportive care in multiple myeloma.Geriatric Assessment to Predict Survival and Risk of Serious Adverse Events in Elderly Newly Diagnosed Multiple Myeloma Patients: A Multicenter Study in China.Population-based cancer registries for quality-of-life research: a work-in-progress resource for survivorship studies?Treatment-related symptom management in patients with multiple myeloma: a review.Development of a conceptual model to illustrate the impact of multiple myeloma and its treatment on health-related quality of life.Long-term health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma receiving lenalidomide and dexamethasone.A systematic review of health-related quality of life in longitudinal studies of myeloma patients.The magnitude of neurotoxicity in patients with multiple myeloma and the impact of dose modifications: results from the population-based PROFILES registry.Elderly multiple myeloma patients experience less deterioration in health-related quality of life than younger patients compared to a normative population: a study from the population-based PROFILES registry.Single vs. multiple fraction regimens for palliative radiotherapy treatment of multiple myeloma : A prospective randomised study.Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective.Variation in fatigue among 6011 (long-term) cancer survivors and a normative population: a study from the population-based PROFILES registry.Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma.Depressive symptoms are a risk factor for all-cause mortality: results from a prospective population-based study among 3,080 cancer survivors from the PROFILES registry.Moving Beyond Maximum Tolerated Dose for Targeted Oncology Drugs: Use of Clinical Utility Index to Optimize Venetoclax Dosage in Multiple Myeloma Patients.Longitudinal validity and reliability of the Myeloma Patient Outcome Scale (MyPOS) was established using traditional, generalizability and Rasch psychometric methods.Guidelines for screening and management of late and long-term consequences of myeloma and its treatment.The effect of pre-transplant pain and chronic disease self-efficacy on quality of life domains in the year following hematopoietic stem cell transplantation.Chemotherapy-induced neuropathy in multiple myeloma: influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice.Self-Reported Quality of Life and Symptom Burden in Ambulatory Patients With Multiple Myeloma on Disease-Modifying Treatment.Multiple primary cancer survivors have poorer health status and well-being than single primary cancer survivors: a study from the population-based PROFILES registry.Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPRelationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS).Best Practice for the Administration of Daratumumab in Multiple Myeloma: Australian Myeloma Nurse Expert Opinion.: holistic needs assessment for haematological cancer patientsImpact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study
P2860
Q30248483-9205A42C-99EC-46B4-893C-65D81B3C7FDFQ30684440-943E1467-1792-4FAE-A83C-22D3EEC2AF3FQ30867463-47218D39-8523-4915-8A5F-98B4364B77D3Q33439437-B2078804-65FE-4830-B580-1FA1EF37D27FQ35032345-F7DA8FAC-DB3B-4B5E-9840-8A4760F98BE9Q35669893-7ADB5DAA-43C6-4BDE-88B5-049FBA6EDB1EQ36069700-0C22391B-B1B2-46C4-BDD1-E74C88405B9CQ37384918-2C450DD0-A2DE-41CC-81F2-69403D6D2C5CQ37426566-D00A8DBF-7BF8-4E6A-B023-15FB5AC97225Q37615538-605784F0-B37D-413E-82ED-42D2BF92EBA7Q38108548-063FD423-CDF8-4EDF-8DE6-EE6CCBCB0E6FQ38342281-C633E386-57AC-4B64-BDAE-8608D53508C9Q38364514-3703356E-6E9F-4722-8C16-2D2987F22007Q38713479-432C8292-DE22-433B-9CBA-76DE54BC44FBQ38742505-2E9255E4-3DFE-44AD-8274-EFAE73F3004DQ39003028-04092542-0995-4FA5-AAE2-BABEE39BFA73Q39084538-D756D8CF-C927-4987-A5BB-E7AD003A80D5Q39154846-68A5BB70-5808-4894-B126-BFDAF3F8B37AQ39737036-794B1ACA-B61C-4B7A-A63D-E9B55EC264D6Q41628533-9FB9AF2D-F203-439E-AB9D-2D75250D4269Q42940568-D8298CA5-89BE-429A-8046-41F86D4CD89CQ44692026-3ECA465D-D053-48BC-9680-3F42AAE618AAQ45057327-21B52B74-8659-40E6-AD2D-1A0FE7E0917AQ47100711-593A04F1-0D5B-4AC8-B84B-639A73287054Q47587127-632D09AF-7A83-4B2E-8704-A4EF29C8C7F3Q47619227-3670BEC4-A1A3-4064-9DC0-A71BE4CE15E5Q47892453-BEED3EDC-3702-4350-AFFA-62DCD1919BB4Q48056468-A87A272B-63FC-41AC-861F-C4E5C08E0578Q48344026-C02EA214-7CAB-4128-A272-95880E42C4B8Q52609413-2EF785AB-A089-4FF1-90F1-2929DA089E3CQ53786308-ABA0D7A5-9D79-462E-91D5-9B0911A07E7CQ55392778-859840C3-2B68-4BAB-B92D-4A9E2AAA6607Q57139801-2C75C445-8910-40F2-B219-73B84C42252BQ58763997-49F5E2E5-83B8-44F5-89B9-BB95CDDCD698
P2860
Health-related quality of life and disease-specific complaints among multiple myeloma patients up to 10 yr after diagnosis: results from a population-based study using the PROFILES registry.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Health-related quality of life ...... y using the PROFILES registry.
@en
Health-related quality of life ...... y using the PROFILES registry.
@nl
type
label
Health-related quality of life ...... y using the PROFILES registry.
@en
Health-related quality of life ...... y using the PROFILES registry.
@nl
prefLabel
Health-related quality of life ...... y using the PROFILES registry.
@en
Health-related quality of life ...... y using the PROFILES registry.
@nl
P2093
P2860
P1476
Health-related quality of life ...... y using the PROFILES registry.
@en
P2093
Allert H Vos
Floortje Mols
Lonneke V van de Poll-Franse
Silvia Verelst
Simone Oerlemans
P2860
P304
P356
10.1111/J.1600-0609.2012.01831.X
P577
2012-08-01T00:00:00Z